Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 137

1.

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.

2.

Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA.

JCI Insight. 2017 Sep 21;2(18). pii: 93265. doi: 10.1172/jci.insight.93265. [Epub ahead of print]

3.

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA.

J Immunother Cancer. 2017 Sep 19;5(1):74. doi: 10.1186/s40425-017-0279-5.

4.

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.

Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK.

J Immunother Cancer. 2017 Aug 15;5(1):67. doi: 10.1186/s40425-017-0272-z.

5.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

6.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

7.

Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.

Seynnaeve B, Lee S, Borah S, Park Y, Pappo A, Kirkwood JM, Bahrami A.

Sci Rep. 2017 Apr 5;7:45704. doi: 10.1038/srep45704.

8.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P.

Oncotarget. 2017 Mar 7;8(10):16367-16386. doi: 10.18632/oncotarget.14829.

9.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

10.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

11.

Downstream consequences of melanoma screening in a community practice setting: First results.

Weinstock MA, Ferris LK, Saul MI, Geller AC, Risica PM, Siegel JA, Solano FX, Kirkwood JM.

Cancer. 2016 Oct 15;122(20):3152-3156. doi: 10.1002/cncr.30177. Epub 2016 Jul 8.

12.

IFN-λ cancer immunotherapy: new kid on the block.

Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM.

Immunotherapy. 2016 Jul;8(8):877-88. doi: 10.2217/imt-2015-0021. Review.

13.

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Review.

14.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

15.

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY.

Cell Rep. 2016 Apr 5;15(1):171-80. doi: 10.1016/j.celrep.2016.03.006. Epub 2016 Mar 24.

16.

Association of TERT promoter mutations with telomerase expression in melanoma.

Lee S, Opresko P, Pappo A, Kirkwood JM, Bahrami A.

Pigment Cell Melanoma Res. 2016 May;29(3):391-3. doi: 10.1111/pcmr.12471. No abstract available.

17.

Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.

Fan Y, Lee S, Wu G, Easton J, Yergeau D, Dummer R, Vogel P, Kirkwood JM, Barnhill RL, Pappo A, Bahrami A.

J Invest Dermatol. 2016 Jan;136(1):339-42. doi: 10.1038/JID.2015.374. No abstract available.

18.

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.

Davar D, Kirkwood JM.

Clin Cancer Res. 2015 Dec 15;21(24):5412-4. doi: 10.1158/1078-0432.CCR-14-3132.

19.

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.

Davar D, Wilson M, Pruckner C, Kirkwood JM.

Case Rep Oncol Med. 2015;2015:737389. doi: 10.1155/2015/737389. Epub 2015 Sep 10.

20.

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.

Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C, Kirkwood JM.

J Transl Med. 2015 Sep 30;13:319. doi: 10.1186/s12967-015-0678-7.

Supplemental Content

Loading ...
Support Center